First Authors
Educational Information Provided with Discount Coupon for Iron Supplements Encourages Coupon Redemption.....Maybe
Dr. Jed B Gorlin, MD, MBA, New York Blood Center, St Paul, MN, Dr. Nancy L Van Buren, MD, Innovative Blood Resources, division of New York Blood Center, St. Paul, MN, Vanessa Reynolds, MLT, New York Blood Center, St. Paul, MN and Mrs. Angela Engblom, MLT, New York Blood Center, Duluth, MN
Saving Transfusable Group O and Rare Red Cells for Patients; Variance Request to FDA to Allow Deferred Donors to be Used for Reagent Red Cell Manufacturing
Susan M. Corby, Dr. Jed B. Gorlin, MD, Kendra Reynolds and Samrith Samnanveth, Innovative Blood Resources, St. Paul, MN
Rapid Implementation of a COVID-19 Convalescent Plasma Program
Alexandra Budhai, MD1, Annie Wu2, Lucette Hall, BS, MBA1, Ms. Donna Strauss, M.S.3, Sarai Paradiso, BS MT(ASCP)3, Jill Alberigo4, Christopher Hillyer, MD1, Betsy Jett, MT(ASCP), QCA, CMQOE(ASQ)1, Aaron A.R. Tobian, PhD, MD2, Evan M. Bloch, MD2, Bruce S. Sachais, MD, PhD1 and Dr. Beth H Shaz, MD5, (1)New York Blood Center, New York, NY, (2)Johns Hopkins University School of Medicine, Baltimore, MD, (3)New York Blood Center, Long Island City, NY, (4)Rhode Island Blood Center, Providence, RI, (5)Duke University, Durham, North Carolina, United States
CID-103, an Anti-CD38 Monoclonal Antibody Demonstrates Decreased RBC Binding and Decreased Interference with Pretransfusion Test Methods
Judith Aeschlimann1, Randall W. Velliquette2, Moriah Blackman1, Alexander Zukiwski3 and Connie M. Westhoff2, (1)Immunohematology and Genomics, New York Blood Center Enterprises, Long Island City, NY, (2)New York Blood Center Enterprises, New York, NY, (3)CASI Pharmaceuticals, Inc., Rockville, MD
Complexity of Antibodies Associated with Jk*01W.01
Randall W. Velliquette1, Robin Smeland-Wagman2, Melanie Oliveira3, Andrew Rossin1, Sunitha Vege1, Jensyn K.C. Sullivan3, Kim Wilson-Sandberg4, Christine Lomas-Francis1, Richard M. Kaufman3 and Connie M. Westhoff1, (1)New York Blood Center Enterprises, New York, NY, (2)Department of Pathology, Brigham and Women's Hospital, Boston, MA, (3)Brigham and Women's Hospital, Boston, MA, (4)Long Island Jewish Medical Center, New Hyde Park, NY
Novel RHCE*ceS with c.462G>T (p.Arg154Ser) Encodes Expression of a D Reactive Epitope
Sunitha Vege1, Judith Aeschlimann2, Christine Lomas-Francis3, Randall W. Velliquette4, Zong Hu5 and Connie M. Westhoff4, (1)Immunohematology and Genomics Laboratory, New York Blood Center Enterprises, Long Island City, NY, (2)Immunohematology and Genomics, New York Blood Center Enterprises, Long Island City, NY, (3)Immunohematology and Genomics Laboratory New York Blood Center Enterprises, New York, NY, (4)New York Blood Center Enterprises, New York, NY, (5)New York Blood Center, New York, NY
RHCE Discrepancies in Apparent R1R1 Individuals: Identification of Novel Null Alleles
Sunitha Vege1, Judith Aeschlimann2, Aaron Gottschalk3, Kelly Winkhart, SBB(ASCP)CM4, Amanda Smith5, Christine Lomas-Francis6 and Connie M. Westhoff3, (1)Immunohematology and Genomics Laboratory, New York Blood Center Enterprises, Long Island City, NY, (2)Immunohematology and Genomics, New York Blood Center Enterprises, Long Island City, NY, (3)New York Blood Center Enterprises, New York, NY, (4)None, Overland Park, KS, (5)New York Blood Center, New York, NY, (6)Immunohematology and Genomics Laboratory New York Blood Center Enterprises, New York, NY
Serological Interference in Patients Receiving SRF231 Anti-CD47 ImmunotherapyRandall W. Velliquette1, Connie Cai1, Gayane Shakarian2, Anna Burgos1, Christine Lomas-Francis2 and Connie M. Westhoff1, (1)Immunohematology and Genomics Laboratory, New York Blood Center Enterprises, New York, NY, (2)Immunohematology and Genomics, New York Blood Center Enterprises, Long Island City, NY